After two years of treatment with bimekizumab, 53.1% of patients experienced mild disease compared to none at baseline.

Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

The methodology, created in the bespoke gen AI-driven biotechnology lab of Cambridge Consultants, part of the Capgemini Group ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis (PPF). The ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Ariceum Therapeutics, a private biotech company based in Berlin, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its proprietary ...

Distributing reliable information about medicines is challenging for the pharma industry and the healthcare professionals ...